These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 9862871)

  • 1. Transient selection of a hepatitis B virus polymerase gene mutant associated with a decreased replication capacity and famciclovir resistance.
    Pichoud C; Seignères B; Wang Z; Trépo C; Zoulim F
    Hepatology; 1999 Jan; 29(1):230-7. PubMed ID: 9862871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro.
    Delaney WE; Yang H; Westland CE; Das K; Arnold E; Gibbs CS; Miller MD; Xiong S
    J Virol; 2003 Nov; 77(21):11833-41. PubMed ID: 14557667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of hepatitis B virus variants resistant to lamivudine and famciclovir among randomly selected chronic carriers from Spain.
    León P; Pozo F; Echevarría JM
    Enferm Infecc Microbiol Clin; 2004 Mar; 22(3):133-7. PubMed ID: 14987532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro evaluation of hepatitis B virus polymerase mutations associated with famciclovir resistance.
    Xiong X; Yang H; Westland CE; Zou R; Gibbs CS
    Hepatology; 2000 Jan; 31(1):219-24. PubMed ID: 10613749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective.
    Melegari M; Scaglioni PP; Wands JR
    Hepatology; 1998 Feb; 27(2):628-33. PubMed ID: 9462667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selection of multiresistant hepatitis B virus during sequential nucleoside-analogue therapy.
    Mutimer D; Pillay D; Cook P; Ratcliffe D; O'Donnell K; Dowling D; Shaw J; Elias E; Cane PA
    J Infect Dis; 2000 Feb; 181(2):713-6. PubMed ID: 10669360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolution of hepatitis B virus polymerase gene sequence during famciclovir therapy for chronic hepatitis B.
    Seignères B; Pichoud C; Ahmed SS; Hantz O; Trépo C; Zoulim F
    J Infect Dis; 2000 Apr; 181(4):1221-33. PubMed ID: 10762559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The sequential occurrence of viral mutations in a liver transplant recipient re-infected with hepatitis B: hepatitis B immune globulin escape, famciclovir non-response, followed by lamivudine resistance resulting in graft loss.
    de Man RA; Bartholomeusz AI; Niesters HG; Zondervan PE; Locarnini SA
    J Hepatol; 1998 Oct; 29(4):669-75. PubMed ID: 9824278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.
    Lada O; Benhamou Y; Cahour A; Katlama C; Poynard T; Thibault V
    Antivir Ther; 2004 Jun; 9(3):353-63. PubMed ID: 15259898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Restoration of replication phenotype of lamivudine-resistant hepatitis B virus mutants by compensatory changes in the "fingers" subdomain of the viral polymerase selected as a consequence of mutations in the overlapping S gene.
    Torresi J; Earnest-Silveira L; Civitico G; Walters TE; Lewin SR; Fyfe J; Locarnini SA; Manns M; Trautwein C; Bock TC
    Virology; 2002 Jul; 299(1):88-99. PubMed ID: 12167344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutational pattern of hepatitis B virus on sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occurring under HBIg immunoglobulin after liver transplantation.
    Tillmann HL; Trautwein C; Bock T; Böker KH; Jäckel E; Glowienka M; Oldhafer K; Bruns I; Gauthier J; Condreay LD; Raab HR; Manns MP
    Hepatology; 1999 Jul; 30(1):244-56. PubMed ID: 10385663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The rtA194T polymerase mutation impacts viral replication and susceptibility to tenofovir in hepatitis B e antigen-positive and hepatitis B e antigen-negative hepatitis B virus strains.
    Amini-Bavil-Olyaee S; Herbers U; Sheldon J; Luedde T; Trautwein C; Tacke F
    Hepatology; 2009 Apr; 49(4):1158-65. PubMed ID: 19263474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation.
    Aye TT; Bartholomeusz A; Shaw T; Bowden S; Breschkin A; McMillan J; Angus P; Locarnini S
    J Hepatol; 1997 May; 26(5):1148-53. PubMed ID: 9186847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus.
    Delaney WE; Edwards R; Colledge D; Shaw T; Torresi J; Miller TG; Isom HC; Bock CT; Manns MP; Trautwein C; Locarnini S
    Antimicrob Agents Chemother; 2001 Jun; 45(6):1705-13. PubMed ID: 11353615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutations in the conserved woodchuck hepatitis virus polymerase FLLA and YMDD regions conferring resistance to lamivudine.
    Tatti KM; Korba BE; Stang HL; Peek S; Gerin JL; Tennant BC; Schinazi RF
    Antiviral Res; 2002 Jul; 55(1):141-50. PubMed ID: 12076758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening and identification of a novel adefovir dipivoxil resistance associated mutation, rtN236V, of HBV from a large cohort of HBV-infected patients.
    Liu Y; Liu W; Li X; Xu Z; Wang X; Li C; Chen L; Xin S; Xu D
    Antivir Ther; 2014; 19(6):551-8. PubMed ID: 24710668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. rtE218G, a novel hepatitis B virus mutation with resistance to adefovir dipivoxil in patients with chronic hepatitis B.
    Liu LJ; Wang JH; Du SC; Tian JH; Yang RF; Wei L
    J Viral Hepat; 2010 Mar; 17 Suppl 1():66-72. PubMed ID: 20586936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC).
    Das K; Xiong X; Yang H; Westland CE; Gibbs CS; Sarafianos SG; Arnold E
    J Virol; 2001 May; 75(10):4771-9. PubMed ID: 11312349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Absence of mutations in the YMDD motif/B region of the hepatitis B virus polymerase in famciclovir therapy failure.
    Günther S; von Breunig F; Santantonio T; Jung MC; Gaeta GB; Fischer L; Sterneck M; Will H
    J Hepatol; 1999 May; 30(5):749-54. PubMed ID: 10365797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence, viral replication efficiency and antiviral drug susceptibility of rtQ215 polymerase mutations within the hepatitis B virus genome.
    Amini-Bavil-Olyaee S; Herbers U; Mohebbi SR; Sabahi F; Zali MR; Luedde T; Trautwein C; Tacke F
    J Hepatol; 2009 Oct; 51(4):647-54. PubMed ID: 19586679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.